Cerebral Hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits

Wayne M. Clark, Ken P. Madden, Patrick D. Lyden, Justin A. Zivin

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


We studied the incidence of cerebral hemorrhage in an animal model of embolic stroke to determine the safety of aspirin, heparin, and tissue plasminogen activator therapies. We occluded the middle cerebral arteries of rabbits with labeled blood clots and administered either tissue plasminogen activator, heparin, aspirin, tissue plasminogen activator plus aspirin, tissue plasminogen activator plus heparin, or saline at various times after stroke. Compared to saline controls, both the aspirin-only and the tissue plasminogen activator-plus-aspirin groups had a significantly higher incidence of cerebral hemorrhage, whereas the heparin and tissue plasminogen activator combination groups did not. We conclude that aspirin antiplatelet therapy alone may increase the risk of hemorrhagic infarction, whereas heparin or tissue plasminogen activator therapy appears to be relatively safe.

Original languageEnglish (US)
Pages (from-to)872-876
Number of pages5
Issue number7
StatePublished - Jul 1991


  • Aspirin
  • Cerebral hemorrhage
  • Rabbits
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing


Dive into the research topics of 'Cerebral Hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits'. Together they form a unique fingerprint.

Cite this